SHANGHAI, Aug. 22, 2023 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights – Collaboration agreement for zevor-cel commercialization in mainland China with Huadong Medicine. – CT041 has achieved IND clearance
Read More
Fakty Miami Top News:
- ‘Jidou Hanbaiki ni Umarekawatta Ore wa Meikyuu wo Samayou’ Gets Second Season
- First Time Ever, Nasa Capsule Brings Major Asteroid Sample to Earth
- Closing date fixed for Oxford Cowley Wilko store
- A food guide to Berlin, from fine dining to kebabs
- Universal Audio 1176, Evermore, Heavenly, and Orion Review
- 3 Ways to Play Like John Mayer
- Jacek Sasin: Nie ma żadnego kryzysu paliwowego
- A look ahead at the NFL season
Sunday, October 1
